Patrick Hwu: Can engineered T-cell therapies offer new hope for patients with advanced soft tissue sarcomas?
Patrick Hwu, President and CEO at Moffitt Cancer Center, shared a post on LinkedIn:
“Can engineered T-cell therapies offer new hope for patients with advanced soft tissue sarcomas?
In this pilot study, D’Angelo et al., with contributions from Mihaela Druta of Moffitt Cancer Center evaluated letetresgene autoleucel (lete-cel), a T-cell receptor therapy targeting NY-ESO-1, in patients with advanced or metastatic myxoid/round cell liposarcoma (MRCLS).
Patients who received standard-dose lymphodepletion before lete-cel infusion had an overall response rate of 40 percent, with disease control in 80 percent of cases. These results show promising antitumor activity in a disease with few effective treatment options.
This study supports the potential of T-cell receptor therapies like lete-cel to improve outcomes for patients with aggressive sarcomas and highlights the critical role of collaborative research.”
Title: Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Authors: Sandra P. D’Angelo, Mihaela Druta, Brian A. Van Tine, David Liebner, Scott M. Schuetze, William D. Tap, Jessica Preston, Sophia Goodison, Jimson W. D’Souza, Gurpreet S. Kapoor, Sunil Suchindran, Stefan Zajic, Aishwarya Bhaskar, Heather Kaczynski, Jaegil Kim, Erika Klohe, Ellie Corigliano, Ioanna Eleftheriadou, Michael J. Nathenson, Neeta Somaiah
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023